These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38403155)

  • 1. A call to rethink the necessity of and challenges facing academic research organizations in the new era of drug innovation in China.
    Huang H; Jiang N; Chen W; Tang Y; Li N
    Drug Discov Today; 2024 Apr; 29(4):103925. PubMed ID: 38403155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation.
    Shi YZ; Hu H; Wang C
    Global Health; 2014 Nov; 10():78. PubMed ID: 25406839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model.
    Goldenberg NA; Spyropoulos AC; Halperin JL; Kessler CM; Schulman S; Turpie AG; Skene AM; Cutler NR; Hiatt WR;
    Blood; 2011 Feb; 117(7):2089-92. PubMed ID: 21068436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials integrity: a CRO perspective.
    Beach JE
    Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The drivers of collaborative innovation of the comprehensive utilization technologies of coal fly ash in China: a network analysis.
    Yu X; Cui Y; Chen Y; Chang IS; Wu J
    Environ Sci Pollut Res Int; 2022 Aug; 29(37):56291-56308. PubMed ID: 35334046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharma CRO industry in China: landscape and opportunities.
    Xia C; Gautam A
    Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Chinese healthcare organizations' innovative performance in the digital health era.
    Gu W; Shu L; Chen W; Wang J; Wu D; Ai Z; Li J
    Front Public Health; 2023; 11():1141757. PubMed ID: 37483948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Challenges and strategies of drug innovation].
    Guo ZR; Zhao HY
    Yao Xue Xue Bao; 2013 Jul; 48(7):1031-40. PubMed ID: 24133969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contract research organizations in oncology clinical research: Challenges and opportunities.
    Roberts DA; Kantarjian HM; Steensma DP
    Cancer; 2016 May; 122(10):1476-82. PubMed ID: 27018651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contract Research Organizations Are Seeking Transformation in the Pharmaceutical Value Chain.
    Huang J
    ACS Med Chem Lett; 2019 May; 10(5):684-686. PubMed ID: 31097979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Future of Contract Research Organizations in Dermatology and Aesthetic Research.
    Nestor M; Pariser D; Del Rosso J; Glaser DA; Goldberg D; Ablon G; Lorenc ZP; Santos J
    J Clin Aesthet Dermatol; 2022 Sep; 15(9):16-19. PubMed ID: 36213607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Future of Contract Research Organizations in Dermatology and Aesthetic Research.
    Nestor M; Pariser D; Del Rosso J; Glaser DA; Goldberg D; Ablon G; Lorenc ZP; Santos J
    J Clin Aesthet Dermatol; 2022 Dec; 15(12 Suppl 1):S28-S31. PubMed ID: 36588785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and analysis of leading position in hydrogen fuel cell vehicle innovation network and the influential factors: a case of patent citations in China.
    Yu P; Cai Z; Jiang F; Sun Y
    Environ Sci Pollut Res Int; 2023 Apr; 30(18):53339-53354. PubMed ID: 36856993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thoughts of the combination of medicine and engineering and collaborative innovation on surgery in China].
    Lyu ZJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jun; 23(6):562-565. PubMed ID: 32521975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obstacles and opportunities in Chinese pharmaceutical innovation.
    Ni J; Zhao J; Ung CO; Hu Y; Hu H; Wang Y
    Global Health; 2017 Mar; 13(1):21. PubMed ID: 28340579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Industry-academic partnerships: an approach to accelerate innovation.
    Chen J; Pickett T; Langell A; Trane A; Charlesworth B; Loken K; Lombardo S; Langell JT
    J Surg Res; 2016 Sep; 205(1):228-33. PubMed ID: 27621024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of proximity and knowledge base on recombination innovation in R&D collaboration.
    Nan D
    PLoS One; 2024; 19(2):e0298735. PubMed ID: 38412178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between the Chinese tobacco industry and academic institutions in China.
    Gan Q; Glantz SA
    Tob Control; 2011 Jan; 20(1):12-9. PubMed ID: 20952560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anatomy of medical research: US and international comparisons.
    Moses H; Matheson DH; Cairns-Smith S; George BP; Palisch C; Dorsey ER
    JAMA; 2015 Jan; 313(2):174-89. PubMed ID: 25585329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical industry-led partnerships focused on addressing the global burden of non-communicable diseases: a review of Access Accelerated.
    Umeh CA; Rockers PC; Laing RO; Wagh O; Wirtz VJ
    Public Health; 2020 Apr; 181():73-79. PubMed ID: 31958672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.